However, ERGAL silencing dramatically down-regulated the gene and protein expression of VE-cadherin and claudin-5, leading to intercellular gap formation, as well as disruptions in the cytoskeletal structure, all of which resulted in the imperfection and instability of vascular endothelial barrier during early infection. The gene discussed is CLDN5; the disease is infection.